Michael Esq - Fortress Biotech Vice Devel

All Insiders . USA . 
Preferred Stock . Fortress Biotech Pref . Stakeholders . Insider . Michael Esq
FBIOP Preferred Stock  USD 5.27  0.12  2.33%   

Insider

Michael Esq is Vice Devel of Fortress Biotech Pref
Age 57
Phone781 652 4500
Webhttps://www.fortressbiotech.com

Fortress Biotech Management Efficiency

The company has return on total asset (ROA) of (0.3494) % which means that it has lost $0.3494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4338) %, meaning that it generated substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Fortress Biotech Pref has accumulated 46.56 M in total debt with debt to equity ratio (D/E) of 0.81, which is about average as compared to similar companies. Fortress Biotech Pref has a current ratio of 2.79, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Fortress Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Fortress Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fortress Biotech Pref sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fortress to invest in growth at high rates of return. When we think about Fortress Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

BSc FRCPathAchilles Therapeutics PLC
59
Steven RuhlForte Biosciences
67
LLM JDRezolute
63
Boyan MDIndaptus Therapeutics
57
FMEDSCI MDAchilles Therapeutics PLC
49
Petpiboon PrasitTempest Therapeutics
N/A
Thomas SchaibleFortress Biotech
N/A
Iraj AliAchilles Therapeutics PLC
49
Thomas BurnsXOMA Corporation
49
Julia WilsonAchilles Therapeutics PLC
N/A
Andrew SleeProtagenic Therapeutics
74
Robert MDProtagenic Therapeutics
73
Karl MDAchilles Therapeutics PLC
57
Dr DubenskyTempest Therapeutics
66
Scott MBAMustang Bio
N/A
MS MBAXOMA Corporation
67
Eliot CPAMustang Bio
66
Justin TrojanowskiTempest Therapeutics
36
Christopher RoenfeldtForte Biosciences
N/A
III CFACheckpoint Therapeutics
46
David LovejoyProtagenic Therapeutics
N/A
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York. Fortress Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people. Fortress Biotech Pref (FBIOP) is traded on NASDAQ Exchange in USA. It is located in 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 and employs 173 people. Fortress Biotech is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Return On Equity-1.43
Return On Asset-0.35

Fortress Biotech Pref Leadership Team

Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO
Samuel Berry, Gen Sec
Robyn Hunter, Ex Officer
Michael Esq, Vice Devel
Thomas Schaible, Project Disease
George Avgerinos, Senior Vice President - Biologics Operations
David Jin, CFO Devel

Fortress Preferred Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right preferred stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Number Of Shares Shorted245

Additional Tools for Fortress Preferred Stock Analysis

When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY